<DOC>
	<DOCNO>NCT01930292</DOCNO>
	<brief_summary>This two-part trial patient squamous non-small cell lung cancer ( NSCLC ) , platinum ( Pt ) -refractory ovarian cancer , basal-like/claudin low triple negative breast cancer ( TNBC ) . The primary objective Part A determine maximum tolerate dose ( MTD ) Debio 1143 administer patient combination full dose paclitaxel carboplatin . The primary objective Part B consolidate safety profile recommend dose Debio 1143 administer patient combination full dose paclitaxel carboplatin .</brief_summary>
	<brief_title>Debio 1143 Combination With Carboplatin Paclitaxel Patient With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Meets protocolspecified criterion qualification contraception Is willing able remain confine study unit entire duration treatment period comply restriction relate food , drink medication Voluntarily consent participate provide write informed consent prior protocolspecific procedure Has history current use overthecounter medication , dietary supplement , drug ( include nicotine alcohol ) outside protocolspecified parameter Has sign , symptom history condition , per protocol opinion investigator , might compromise : 1. safety wellbeing participant study staff ; 2. safety wellbeing participant 's offspring ( pregnancy breastfeed ) ; 3. analysis result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>